- Home
- FCEL vs FHTX Comparison
FCEL vs FHTX Comparison
Compare FCEL & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- FHTX
- Stock Information
- Founded
- FCEL 1969
- FHTX 2015
- Country
- FCEL United States
- FHTX United States
- Employees
- FCEL N/A
- FHTX 112
- Industry
- FCEL Industrial Machinery/Components
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- FCEL Energy
- FHTX Health Care
- Exchange
- FCEL Nasdaq
- FHTX Nasdaq
- Market Cap
- FCEL 273.9M
- FHTX 246.6M
- IPO Year
- FCEL 1992
- FHTX 2020
- Fundamental
- Price
- FCEL $7.06
- FHTX $4.68
- Analyst Decision
- FCEL Hold
- FHTX Strong Buy
- Analyst Count
- FCEL 4
- FHTX 6
- Target Price
- FCEL $8.91
- FHTX $11.83
- AVG Volume (30 Days)
- FCEL 3.5M
- FHTX 263.6K
- Earning Date
- FCEL 12-18-2025
- FHTX 11-05-2025
- Dividend Yield
- FCEL N/A
- FHTX N/A
- EPS Growth
- FCEL N/A
- FHTX N/A
- EPS
- FCEL N/A
- FHTX N/A
- Revenue
- FCEL $152,472,000.00
- FHTX $24,518,000.00
- Revenue This Year
- FCEL $34.50
- FHTX $42.43
- Revenue Next Year
- FCEL $25.64
- FHTX $14.77
- P/E Ratio
- FCEL N/A
- FHTX N/A
- Revenue Growth
- FCEL 78.81
- FHTX N/A
- 52 Week Low
- FCEL $3.58
- FHTX $2.95
- 52 Week High
- FCEL $13.98
- FHTX $8.98
- Technical
- Relative Strength Index (RSI)
- FCEL 42.76
- FHTX 57.13
- Support Level
- FCEL $6.98
- FHTX $4.33
- Resistance Level
- FCEL $7.76
- FHTX $4.60
- Average True Range (ATR)
- FCEL 0.81
- FHTX 0.37
- MACD
- FCEL -0.14
- FHTX 0.08
- Stochastic Oscillator
- FCEL 14.82
- FHTX 95.95
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.